Market data

Select a section

Poolbeg Pharma

(POLB)
Sector: Pharmaceuticals & Biotechnology
7.73p
-0.02p -0.22
Last updated: 10:50:00

Company News Headlines

Date Time Headline Source
20/11/2024 07:00 POLB 001 Patent Granted in United States RNS
18/09/2024 07:00 Interim results for the six months to 30 June 2024 RNS
12/08/2024 13:28 Holding(s) in Company RNS
26/07/2024 07:00 Voluntary Delisting from OTCQB Market RNS
10/07/2024 07:00 Notification of Major Holdings RNS
02/07/2024 07:00 Change of Registered Address RNS
17/06/2024 08:38 Result of AGM RNS
09/05/2024 07:00 Annual Report & AGM Notice RNS
01/05/2024 07:00 Significant POLB 001 Patent Granted in USA RNS
30/04/2024 07:02 Appointment of Joint Broker RNS
30/04/2024 07:00 Results for the year ended 31 December 2023 RNS
30/04/2024 07:01 Option Agreement to Acquire Orphan Drug Candidate RNS
29/04/2024 07:00 TR-1: Notification of major holdings RNS
22/02/2024 07:00 Director/PDMR Shareholding RNS
19/02/2024 13:42 Director Share Purchase RNS
15/02/2024 07:00 Board Role Change and Launch of EIP RNS
17/01/2024 07:00 Further data shows POLB001 potential in cancer CRS RNS
20/12/2023 07:00 RSV AI Drug Candidate Analysis Update RNS
11/12/2023 07:00 POLB 001 Data Presented at ASH RNS
30/11/2023 07:00 Directorate Change RNS
09/11/2023 07:00 Former Amryt Pharma Leadership Team join Poolbeg RNS
03/11/2023 07:05 POLB001 Data to be Presented at ASH Annual Meeting RNS
01/11/2023 07:00 POLB 001 Oncology Programme Update Meeting RNS
17/10/2023 07:00 Poolbeg Partners with a Nasdaq-Listed Biopharma RNS
29/09/2023 07:00 Favourable Conclusion of Patent Opposition RNS
19/09/2023 07:00 Immunomodulator I Patent Opposition Withdrawal RNS
13/09/2023 07:00 Interim results for the six months to 30 June 2023 RNS
29/06/2023 07:00 AI led programme identifies influenza drug targets RNS
22/06/2023 07:00 Oral Vaccine Programme Moves Forward RNS
24/05/2023 07:00 Board Appointment RNS
11/05/2023 14:27 Results of Annual General Meeting RNS
12/04/2023 07:00 Annual Report & AGM Notice RNS
30/03/2023 07:00 Results for the year ended 31 December 2022 RNS
10/03/2023 07:00 Notification of Major Holdings RNS
09/03/2023 15:51 Notification of Major Holdings RNS
02/03/2023 11:05 Second Price Monitoring Extn RNS
02/03/2023 11:00 Price Monitoring Extension RNS
02/03/2023 07:00 Positive Results POLB001 LPS Human Challenge Trial RNS
16/01/2023 07:00 Strategic expansion of POLB 001 into oncology RNS
09/01/2023 09:05 Second Price Monitoring Extn RNS
09/01/2023 09:00 Price Monitoring Extension RNS
09/01/2023 07:00 Positive Initial Data Analysis in POLB 001 Trial RNS
22/12/2022 10:48 Poolbeg Pharma identifies new RSV drug candidates EQS Group
21/12/2022 07:00 Poolbeg identifies novel RSV drug candidates RNS
15/12/2022 09:49 Poolbeg Pharma makes 'interesting addition to existing collaboration' EQS Group
14/12/2022 07:00 Metabolic diseases oral delivery licence signed RNS
12/12/2022 14:05 Second Price Monitoring Extn RNS
12/12/2022 14:00 Price Monitoring Extension RNS
12/12/2022 12:00 Poolbeg Pharma receives initial results from human challenge clinical study EQS Group
12/12/2022 07:00 POLB 001 LPS human challenge trial completed RNS

Market data

Select a section